Meridian Bioscience Inc. (NASDAQ:vivo) declared a quarterly dividend on Thursday, November 10th. Shareholders of record on Monday, November 21st will be paid a dividend of 0.20 per share on Thursday, December 1st. This represents a $0.80 dividend on an annualized basis and a yield of 4.69%. The ex-dividend date of this dividend is Thursday, November 17th.

Meridian Bioscience (NASDAQ:VIVO) opened at 17.05 on Friday. Meridian Bioscience has a 52 week low of $15.75 and a 52 week high of $21.49. The firm has a market capitalization of $717.57 million, a P/E ratio of 20.30 and a beta of 0.94. The firm has a 50-day moving average price of $17.98 and a 200-day moving average price of $19.06.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.14. The firm earned $47 million during the quarter, compared to analysts’ expectations of $47.17 million. Meridian Bioscience had a net margin of 17.95% and a return on equity of 21.51%. Meridian Bioscience’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. Equities analysts forecast that Meridian Bioscience will post $0.80 EPS for the current year.

Dividend History for Meridian Bioscience (NASDAQ:vivo)

A number of brokerages recently issued reports on VIVO. Zacks Investment Research cut shares of Meridian Bioscience from a “hold” rating to a “strong sell” rating in a report on Friday, October 21st. Canaccord Genuity restated a “neutral” rating and set a $18.00 price target on shares of Meridian Bioscience in a report on Wednesday, October 19th. Finally, Hilliard Lyons cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Friday, July 29th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.00.

In related news, EVP Lawrence Baldini acquired 4,900 shares of the business’s stock in a transaction dated Thursday, November 3rd. The stock was acquired at an average price of $16.00 per share, with a total value of $78,400.00. Following the completion of the transaction, the executive vice president now owns 95,501 shares of the company’s stock, valued at $1,528,016. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman John A. Kraeutler acquired 5,000 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were bought at an average cost of $16.13 per share, with a total value of $80,650.00. Following the transaction, the chairman now directly owns 316,683 shares of the company’s stock, valued at approximately $5,108,096.79. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System raised its position in shares of Meridian Bioscience by 1.4% in the second quarter. Arizona State Retirement System now owns 21,841 shares of the company’s stock worth $426,000 after buying an additional 300 shares in the last quarter. BlackRock Inc. raised its position in shares of Meridian Bioscience by 7.3% in the third quarter. BlackRock Inc. now owns 5,810 shares of the company’s stock worth $112,000 after buying an additional 395 shares in the last quarter. KCG Holdings Inc. raised its position in shares of Meridian Bioscience by 3.5% in the third quarter. KCG Holdings Inc. now owns 12,313 shares of the company’s stock worth $238,000 after buying an additional 420 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Meridian Bioscience by 0.9% in the third quarter. California State Teachers Retirement System now owns 88,249 shares of the company’s stock worth $1,702,000 after buying an additional 800 shares in the last quarter. Finally, BlackRock Advisors LLC raised its position in shares of Meridian Bioscience by 4.4% in the second quarter. BlackRock Advisors LLC now owns 20,604 shares of the company’s stock worth $402,000 after buying an additional 876 shares in the last quarter. 86.99% of the stock is owned by institutional investors and hedge funds.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

5 Day Chart for NASDAQ:VIVO

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.